Therapeutic inertia or individualization? Delay in clinical management of type 2 diabetes mellitus

Nagaaki TanakaCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan; ;Kansai Electric Power Medical Research Institute, Osaka, JapanCorrespondence[email protected]

Takeshi KuroseCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan; ;Kansai Electric Power Medical Research Institute, Osaka, Japan

Yutaka SeinoCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan; ;Kansai Electric Power Medical Research Institute, Osaka, Japan

References

American Diabetes Association. Standards of medical care in diabetes – 2016. Diabetes Care 2016;39(Suppl 1):S39–46
PubMed Web of Science ®Google Scholar
The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–59
PubMed Web of Science ®Google Scholar
Nathan D, Buse J, Davidson J, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193–203
PubMed Web of Science ®Google Scholar
Phillips L, Branch T Jr, Cook C, et al. Clinical Inertia. Ann Intern Med 2001;135:825–34
PubMed Web of Science ®Google Scholar
Watson L, Das R, Farquhar R, et al. Consequences of delaying treatment intensification in type 2 diabetes: evidence from a UK database. Curr Med Res Opin 2016; Mar 23: 1-11. [Epub ahead of print] DOI:10.1185/03007995.2016.1157462
PubMedGoogle Scholar
Shah B, Hux J, Laupacis A, et al. Clinical inertia in response to inadequate glycemic control. Diabetes Care 2005;28:600–6
PubMed Web of Science ®Google Scholar
Paul S, Klein K, Thorsted B, et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol 2015;14:100–9
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Therapeutic inertia or individualization? Delay in clinical management of type 2 diabetes mellitus

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Therapeutic inertia or individualization? Delay in clinical management of type 2 diabetes mellitus

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date